Serological markers of hepatitis delta virus (HDV) infection were found in 18 (12^o) of 146 consecutive patients with chronic hepatitis B, and the characteristics of patients who had antibody to HDV (anti-HDV-positive) were analyzed. During one to 15 years of followup, histological deterioration was documented in 77^0 of anti-HDV-positive patients; however, in hepatitis B surface antigen (HBsAg) carriers without HDV infection, histology deteriorated in 30^0 but improved or remained unchanged in the majority of patients (P < .01). In seven (70^0) of the 10 anti-HDV-positive patients who showed transition from chronic active hepatitis to cirrhosis, this event was observed within the first two years of follow-up. The probability of evolution to cirrhosis was significantly higher in anti-HDV-positive patients than in patients without antibody to HDV (P < .001). These findings indicate that HDV infection in patients with chronic hepatitis B is associated with a more-rapid progression to cirrhosis compared with HBsAg carriers with chronic hepatitis and no evidence of HDV infection. We have investigated the prevalence and clinical significance of HDV infection in a large series of consecutive hepatitis B surface antigen (HBsAg)-positive patients with chronic liver disease. We report here the main clinical and laboratory aspects of HDVpositive chronic liver disease in these patients who were followed-up for a mean period of observation of approximately five years. The features of HDVpositive patients were compared with those of patients who were HDV negative and who had chronic type B liver disease.
The hepatitis delta virus (HDV) is highly pathogenic and is responsible for acute and chronic liver disease [1] . Previous clinical studies have suggested that HDV infection is associated with severe liver disease in chronic carriers of the hepatitis B virus (HBV) [2] ; however, a comparison of the outcome in HDVpositive and HDV-negative patients has been reported in few studies [3, 4] .
We have investigated the prevalence and clinical significance of HDV infection in a large series of consecutive hepatitis B surface antigen (HBsAg)-positive patients with chronic liver disease. We report here the main clinical and laboratory aspects of HDVpositive chronic liver disease in these patients who were followed-up for a mean period of observation of approximately five years. The features of HDVpositive patients were compared with those of patients who were HDV negative and who had chronic type B liver disease.
Patients and Methods
Patients. One hundred forty-six consecutive HBsAg-positive patients, who were referred to our Liver Center for clinical and biochemical features of chronic hepatitis, were included in this study on the basis of the following criteria: (I) HBsAg posi: tivity with increased aminotransferase activities for at least 12 months; (2) liver histology of chronic hepatitis; (3) subsequent follow-up period after histological diagnosis of at least 12 months. All these patients were studied longitudinally for one to 15 years (mean ? SD, 4.7 ? 2.8 years). Routine follow-up studies included clinical assessment, conventional liver function tests, and serological HBV and HDV markers.
There were 111 men and 35 women. Their mean age was 34 ? 13 years (range, 15-67 years). One hundred twenty-seven patients were of northern Italian origin, and 19 were from southern Italy.
The histological diagnosis in the first and in follow-up biopsies was defined according to previously described criteria [5] . Liver biopsies without signs of liver cell necrosis and inflammation and with no evidence of fibrosis and regenerative nodules were classified as normal liver.
Forty-three patients received corticosteroids at conventional doses for periods of six to 45 months, because of severe histological activity, symptoms, and hypergammaglobulinemia, and early cases were treated on the basis of histological evidence of chronic active hepatitis (CAH).
Assays. HBsAg, hepatitis B e antigen (HBeAg), and antibody to hepatitis B e antigen (anti-HBe) were detected by RIA by using commercial reagents (Abbott Laboratories, North Chicago, 111). Antibody to hepatitis delta virus (anti-HDV) was measured and titered by blocking RIA (Abbott Laboratories). HDV infection was diagnosed on the basis of detecting anti-HDV in serum and/or hepatitis delta antigen (HDAg) in the liver by direct immunofluorescence using FITC-conjugated antibody to HDV, as previously described [ tus. The histological evolution of 93 HBsAg carriers who underwent a control liver biopsy during the observation period is shown in table 3. Most of the patients with HDV infection (77^0) showed deterioration, and in a minority of these patients (23 Vo) histology remained unchanged. No one showed histological improvement. In anti-HDV-negative patients, the follow-up biopsies did not change in 39^0 of the patients, showed improvement in 31Vo, and deteriorated in 30Vo. These differences in histological outcome were statistically significant (P < .01, X2 test in 2 x 3 table). Table 4 describes the histological follow-up of the 93 patients submitted to a repeat liver biopsy, in relation to immunosuppressive therapy. The separate analysis of the anti-HDV-positive and anti-HDV-negative patients revealed a deleterious effect of steroids only in the anti-HDV-positive group (P < .05, x2 test).
The probability of developing cirrhosis, as calculated in the homogeneous group of 88 patients presenting with CAH, was significantly (/K .001) higher in anti-HDV-positive than in anti-HDV-negative patients (figure 1).
Discussion
In our study, the prevalence of chronic HDV infection in HBsAg-positive carriers was lower (12.3 Vo) than that reported in northwestern Italy (18^0-31^0) and southern Italy (20(7o-51(7o) [7] . This low figure approximates that in other parts of Europe [8] . In contrast to patients in the industrial centers of northern Italy, where a consistent proportion of HDVinfected carriers were of southern origin [7] , the majority of the anti-HDV-positive patients who were referred to our institution were natives of Padua. Only half of these anti-HDV-positive patients were HBsAg carriers with a history of parenteral exposure, a factor suggesting that a focus of HDV endemicity might have been established in our region, in agreement with data from a previous survey [7] .
The incidence of drug addicts in our anti-HDV-positive patients was, however, higher than in HBsAg carriers without HDV-positive serology. This finding is consistent with the demonstration that in drug addicts with HBV infection, concurrent infection with the delta agent is common and possibly a major cause of liver disease [9] .
In agreement with other epidemiological findings of HDV infection, anti-HDV-positive liver disease was prevalent in young men [9, 10] , and a characteristic feature of these patients was the frequent history of previous acute hepatitis, which could in fact represent the clinical expression of superinfection with the delta agent.
Serum anti-HBe positivity rather than HBeAg positivity was seen in the majority of our patients with HDV infection, this finding being in agreement with the demonstration that HDV suppresses synthesis of HBV genome and gene products [11] and with the observation that in areas where the HDV is endemic, most patients with chronic HDV infection are positive for anti-HBe and negative for HBV-DNA polymerase in serum [2, 10] .
Compared with anti-HDV-negative patients, our patients with anti-HDV in serum had more-active and severe liver disease at presentation. Clinical and histological features during follow-up indicated a progressive deterioration of liver lesions in a significant proportion of anti-HDV-positive patients (77Vo). In contrast, in HBsAg carriers without HDV infection, histology deteriorated in 30^0, but improved or remained unchanged at the end of followup in the majority of the patients. The difference in the outcome of liver disease between anti-HDV-positive and anti-HDV-negative patients was statistically significant, a result indicating that HDV infection modifies the natural course of HBVassociated liver disease, with a more-rapid evolution to cirrhosis. The outcome of the anti-HDV-positive patients was not influenced by immunosuppressive therapy, which in fact proved deleterious in the anti-HDV-negative patients. These results confirm the major role played by the delta agent in determining the progression of HBsAg-positive liver disease. Few anti-HDV-positive patients showed biochemical remission of liver disease activity during follow-up, but this event did not imply a favorable outcome because it occurred only in patients who had already developed cirrhosis. In conclusion, in our geographic area, HDV infection has a low prevalence among HBsAg chronic carriers, affects mainly young, antiHBe-positive men, and is associated with a morerapid progression to cirrhosis. These characteristics differ from those for anti-HDV-negative carriers who have chronic liver disease.
